β2-AR agonists represent therefore obvious candidates to be tested on CD4+ T cells from PD patients for their ability to correct dysfunctional responses such as Th1-biased differentiation of CD4+ naïve T cells and increased production of Th1 cytokines insensitive to Treg inhibition. Here, CD4 is linked to Parkinson disease.